The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
BUSINESS
7 Companies Launch E Keppra Generics upon Listing
A total of seven companies released their versions of UCB’s mainstay epilepsy drug E Keppra (levetiracetam) on December 10 upon their NHI price listing including two of Big 3 generic players - Nichi-Iko Pharmaceutical and Towa Pharmaceutical. The products of…
To read the full story
Related Article
BUSINESS
- Leqembi’s FY2024 Sales at 44.3 Billion Yen: Eisai
May 7, 2025
- Lilly’s Eczema Drug Ebglyss Now Available for Self-Injection
May 7, 2025
- Kyowa Kirin’s Q1 Profits Down Over 50% on Higher R&D Spending
May 7, 2025
- Satsuma’s Nasal Powder Drug for Migraine Approved in US
May 7, 2025
- Otsuka's Profit Might Drop by Billions if US Imposes 25% Tariff
May 7, 2025
Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…